AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma.

Read the full 268 word article

User Sign In